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Purpose: Primary malignant solitary ﬁbrous tumor (SFT) of the orbit is a rare spindle cell neoplasm that
requires excisional biopsy for histopathological diagnosis. We present a clinical case using contemporary
immunohistochemical stains, report on the latest World Health Organization classiﬁcation, and provide a
review of the literature.
Observations: Report of a single case of a 65 year old male who presented with right-sided proptosis,
limited adduction, ptosis, lateral globe displacement, and cheek festooning. Neuroimaging revealed a 2.2
cm, extraconal heterogeneous mass that diffusely enhanced.
En-bloc tumor resection conﬁrmed SFT malignancy based upon nuclear atypia, hypercellularity, and
increased mitotic activity (13 mitotic ﬁgures/10 high powered ﬁelds). Ki-67 showed 2% nuclear staining
in the benign tumor and 10e15% staining in the malignant counterpart. Immunohistochemical analysis
revealed diffuse Stat6 positivity, CD 34 positivity with partial lack of staining within the malignant
portion, S-100 positivity in the malignant portion, and overall negativity for CAM 5.2, desmin, actin, CD
31, and CD 117.
Conclusions and importance: Immunoproﬁling is helpful to making the diagnosis of malignant solitary
ﬁbrous tumor of the orbit. Complete tumor resection continues to be the preferred treatment. The
behavior of extrathoracic SFT is unpredictable, and patients with SFT in all locations require careful, long-
term follow-up.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Initially described in the pleura by Stout in 1942, solitary ﬁbrous
tumors (SFT) are rare spindle cell neoplasms of mesenchymal
origin. Today, SFTs comprise a spectrum of tumors ranging from
those arising from the pleura with associated paraneoplastic syn-
dromes such as hypoglycemia, to multiple soft tissue sites and the
meninges.1 Primary malignant orbital SFT, however, is a rare entity.
We report an additional case that was diagnosed based upon cur-
rent histopathology and immunoproﬁling techniques.t USC, 1450 San Pablo Street,
ickrema), burnstin@usc.edu
Saber), narsing.rao@med.usc.
reet, Suite 5900, Los Angeles,
ena, CA 91105, USA.
ealth Sciences Campus, Los
Inc. This is an open access article u2. Case report
A 65 year old male presented with persistent swelling and
discharge from the right eye for over nine months. Best corrected
visual acuity was noted to be 20/40 and 20/25 in the right and left
eyes, respectively. Pupils were round and reactive without afferent
pupillary defect, visual ﬁelds were normal to confrontation, and
intraocular pressures were normal in both eyes. On external ex-
amination, the patient had limitation on adduction of the right eye
resulting in binocular horizontal diplopia on left gaze. The patient
also had right upper eyelid ptosis and conjunctival injection that
had been previously attributed to allergic conjunctivitis. Dilated
funduscopic examination was normal without signs of disc edema,
optic atrophy, or choroidal folds. Neuroimaging revealed a 2.2 cm
heterogeneously enhancing right medial extraconal mass (Fig. 1).
The patient underwent a transcaruncular orbitotomy for biopsy,
which revealed solitary ﬁbrous tumor based on positive staining for
CD34 and BCL2 on histopathological analysis. Subsequent en bloc
orbital tumor removal revealed a malignant solitary ﬁbrous tumornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(13 mitotic ﬁgures/10 high powered ﬁelds). Ki-67 showed 2% nu-
clear staining in the benign tumor and 10e15% staining in the
malignant counterpart. Immunohistochemical analysis revealed
diffuse Stat6 positivity, CD 34 positivity with partial lack of staining
within the malignant portion, S-100 positivity in the malignant
portion, and overall negativity for CAM 5.2, desmin, actin, CD 31,
and CD 117 (Fig. 2). The case and histology have been carefully
reviewed by two pathologists. Since resection, the patient con-
tinues to be tumor free at approximately eighteen months in
follow-up.3. Discussion
Two percent of solitary ﬁbrous tumors arise from soft tissue and
typically affect individuals in their ﬁfties. Hypoglycemia has been
described; and ten to ﬁfteen percent of patients have metastases at
the time of diagnosis.1 In 2013, the World Health Organization
reclassiﬁed extrapleural solitary ﬁbrous tumors to be a “ubiquitous
mesenchymal tumor of ﬁbroblastic type,” which shows a promi-
nent “branching vascular pattern,” and rescinded the term,
“hemangiopericytoma” (HPC).2
Historically, the term ‘hemangiopericytoma’ has been used to
describe lesions with a characteristic “staghorn” branching vascular
pattern. However, it appears that it may have been a misnomer;
and in fact this growth pattern is shared by unrelated entities that
are both benign and malignant. In 2006, Gengler and Guillou pro-
posed categorizing these HPC-like tumors into lesions that infre-
quently display the characteristic features (i.e. synovial sarcoma),
clearly show “myoid/pericytic differentiation” that are usually
benign (i.e. glomangiopericytoma/myopericytoma, infantile myo-
ﬁbromatosis, and a subset of sinonasal HPCs), and those that are
solitary ﬁbrous tumors, which also includes ﬁbrous-to-cellular le-
sions (i.e. giant cell angioﬁbromas and lipomatous HPCs).3
Orbital SFTs can present as unilateral proptosis, eyelid swelling,
or dysmotility. Diagnostically, they are indolent lesions that are
oftentimes heterogeneous with low T2 signal intensity on MRI.1,4
Tumor excision typically reveals well circumscribed, partially
encapsulated, colorless masses that are ﬁrm andmultinodular. SFTsFig. 1. Patient Characteristics: Patient presents with right-sided exophthalmos, lateral glo
computed tomography scans reveal a large, enhancing, extraconal mass displacing the globare oftentimes benign with intermediate biologic potential due to
low rates of local recurrence or metastasis.2,4 Clinical and radio-
logical features, however, do not necessarily correlate with histo-
logical signs of malignancy.
It is important to establish the diagnosis of malignant SFT
because of their higher mortality rate. Immunohistochemical
analysis continues to be the gold standard for diagnosis. Histolog-
ical analysis of SFT reveals mixed hypo and hypercellular regions
delineated by hyalinized collagen and thin vessels, as well as
frequent myxoid changes and rare mitotic ﬁgures. Tumor cells
usually stain positive for speciﬁc markers such as CD34 (90e95%)
and Stat6, but variably to S-100 protein, keratin, and desmin.2e6
In contrast, locally aggressive or malignant SFTs can show in-
terval increase in size, increased cell mitoses, atypia, necrosis with
and without hemorrhage, and inﬁltration into adjacent structures.
Mitotic index appears to be the best prognostic indicator to date.2
Areas of malignancy are typically CD 34 negative, while positive
for Stat6, S-100, p53, cytokeratin, and certain gene fusion variants
of NAB2-STAT6 (Table 1).1e4,6e9
Long term follow-up is essential. Further efforts to identify
signaling pathways that lead to tumor dedifferentiation and ma-
lignant transformation will likely establish prognostic indicators
and targets for multimodal therapy. Currently, the identiﬁcation of
signaling pathways that portend poor prognosis has yet to be fully
elucidated. Recent biomolecular studies suggest the potential role
of the nuclear signal transducer and activator of transcription 6
(STAT6) gene, given the discovery of NGFI-A binding protein 2
(NAB2)-STAT6 as a SFT-speciﬁc fusion gene.8,9 However, while Stat6
is a highly speciﬁc marker for SFTs, the prognostic role of various
NAB2-STAT6 fusion genes in determining disease free survival re-
mains unclear.6,10 Future studies will continue to delineate the
oncogenic cascade in malignant SFTs, and these genes may impact
overall prognostication and serve as designer therapy targets.4. Conclusions
Complete surgical resection with long term follow-up and lon-
gitudinal neuroimaging to monitor for recurrence is essential.
Locally advanced, recurrent, or metastatic extrapleural SFT lesionsbe displacement, upper eyelid ptosis, and diminished adduction. Axial and coronal
e laterally.
Fig. 2. Histopathological Findings: A-E. Hematoxylin and eosin (low power benign, transition, malignant zones; high power transition, malignant zones) F-H. CD-34 (low power
positivity in benign, low and high power areas of decreasing staining within malignant zone) I-J. Ki-67 (high power differential staining in benign (2%) and malignant (10e15%)
zones). K. Stat6 (low power diffuse positivity in benign, malignant, and transition areas). L. S-100 (low power positivity in malignant portion of transition zone).
Table 1
Radiographic and Immunohistochemical Markers of Benign vs. Malignant Solitary Fibrous Tumor.
SFTs Ultrasound CT MRI Pathology Immunohistochemistry
Benign Well circumscribed,
homogenous,
echo-lucent
Heterogeneous
enhancement
Heterogeneous enhancement,
isointense (T1), hypointense (T2)
Spindle cells arranged in fascicular pattern,
vascular channels, þ/ cysts
CD34þ
STAT6þ
Malignant þ/ invasion of surrounding
structures
Interval increase in size, þ/ invasion of
adjacent structures
Mitoses (>4 per 10 HPF), cellularity,
pleomorphism, necrosis þ/- hemorrhage
CD34
STAT6þ
S100þ
P53þ
Cytokeratinþ
þ/ NAB2-STAT6þ
*Abbreviations: CT, computed tomography; HPF, high-power ﬁelds; MRI, magnetic resonance imaging, SFT, solitary ﬁbrous tumor.
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therapy.1,11,12 Due to the rarity of these tumors, the role of radiation
and combination chemotherapy remains controversial.
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